SMMT Summit Therapeutics Inc.

Nasdaq summittxinc.com


$ 21.91 $ -0.22 (-0.97 %)    

Tuesday, 14-Oct-2025 12:24:02 EDT
QQQ $ 600.51 $ 5.30 (0.89 %)
DIA $ 462.89 $ 5.88 (1.29 %)
SPY $ 663.54 $ 6.22 (0.95 %)
TLT $ 90.56 $ -0.08 (-0.09 %)
GLD $ 380.03 $ 1.73 (0.46 %)
$ 22.93
$ 22.10
$ 21.89 x 200
$ 21.91 x 66
$ 21.27 - $ 22.16
$ 15.55 - $ 36.91
5,565,944
na
17.03B
$ 0.34
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-01-2025 03-31-2025 10-Q
3 02-24-2025 12-31-2024 10-K
4 10-30-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-01-2024 03-31-2024 10-Q
7 02-20-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-09-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-17-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-17-2021 03-31-2021 10-Q
19 03-31-2021 12-31-2020 10-K
20 11-16-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 intel-marvell-electronic-arts-are-among-the-top-10-large-cap-gainers-last-week-sep-22---sep-26-are-the-others-in-your-portfolio

These ten large-cap stocks were top performers last week. Are they a part of your portfolio?

 nvidia-high-fives-palantir-rocket-lab--on-this-list-of-10-bagger-legends

Ten stocks in the large-cap Russell 1000 index have achieved at least 1,000% returns since the October 2022 bull market bottom,...

 barclays-initiates-coverage-on-summit-therapeutics-with-underweight-rating-announces-price-target-of-13

Barclays analyst Etzer Darout initiates coverage on Summit Therapeutics (NASDAQ:SMMT) with a Underweight rating and announce...

 hc-wainwright--co-reiterates-buy-on-summit-therapeutics-maintains-50-price-target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $50...

 jim-cramer-ring-the-register-on-this-real-estate-meme-stock

On CNBC's "Mad Money Lightning Round," Jim Cramer recommended ditching Opendoor: "We don't want to be in a ...

 synopsys-chewy-and-the-trade-desk-are-among-top-10-large-cap-losers-last-week-sep-8--sep-12-are-the-others-in-your-portfolio

Earnings misses, weak guidance, and downgrades drove large-cap decliners—led by Synopsys, Chewy, and The Trade Desk—while biote...

 cantor-fitzgerald-reiterates-overweight-on-summit-therapeuticsto-overweight

Cantor Fitzgerald analyst Eric Schmidt reiterates Summit Therapeutics (NASDAQ:SMMT) from Overweight to Overweight.

 summit-therapeutics-lung-cancer-drug-under-dark-clouds-as-keytruda-challenger-shows-regional-data-differences

Summit's ivonescimab showed improved survival trends in NSCLC patients with favorable safety, though some results missed st...

 hc-wainwright--co-reiterates-buy-on-summit-therapeutics-maintains-50-price-target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $50...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION